Amarin Corp Plc (AMRN)

[concapk]

STS66

AMARIN conceded that VASCEPA reduced high tri's in some patients within 4 weeks and stayed at that level for the remaining weeks of a twelve week study ( marine study only )... GENERICS jumped on that... their label would be identical to Vascepa which would lower high tri's also but would not be for a chronic condition....

Amarins patent used the ( TWELVE WEEK MARINE STUDY results in their lanquage for the patent approval... generics just claimed they could get results under twelve weeks also...